Januvia (Sitagliptin) in Healing Chronic Diabetic Foot Ulcers

• ClinicalTrials.gov Identifier: NCT02015910
• Recruitment Status: Terminated
• First Posted: December 19, 2013
• Results First Posted: January 6, 2017
• Last Update Posted: January 6, 2017
• Sponsor: Georgetown University
• Collaborator: Merck Sharp & Dohme Corp.
• Information provided by (Responsible Party): Paul J. Kim, DPM, Georgetown University

Study Description

Brief Summary:

The primary objective of this study is to compare the rate of healing as well as percent of wounds healed in Type II diabetic patients with chronic foot ulcerations receiving sitagliptin versus placebo.

The hypothesis for this study is that subjects receiving daily doses of sitagliptin in combination with their regular antihyperglycemic medications will result in increased healing rates as well as a greater number of healed wounds as compared to subjects receiving placebo and their regular antihyperglycemic medications.

Condition or disease	Intervention/treatment	Phase
Type II Diabetes	Drug: Sitagliptin; Drug: Placebo	Phase 4

Detailed Description:

Diabetes and diabetes related complications are a major cost burden on the healthcare system encompassing 1/5 of the overall healthcare dollars in the United States [1]. Much of the costs are related to the treatment of lower extremity wounds in the diabetic patient which accounts for 60% of all nontraumatic amputations that are performed [2]. Amputation is often preceded by a chronic ulceration. The incidence of diabetic ulcers is approximately 6% over a 3 year period [1]. Diabetic foot ulcerations are particularly challenging to heal due to a host of factors including vascular compromise, peripheral neuropathy, and begin prone to infection. Therefore, strategies to heal these wounds as quickly as possible are of paramount importance.

Current strategies for chronic wound healing are limited to topical ointments/therapies, allografts/xenografts with or without cell impregnation, dressings, and wound healing devices. None of these current modalities have been shown to be clearly more effective than another [3,4]. Currently, oral medications have not been examined for healing of these chronic ulcerations. Particularly, antihyperglycemic medications have not been studied specifically for the purpose of wound healing. Glucose control and wound healing have been shown to be related [5-7]. However, it is thought that wound healing as a result of tighter glucose control is merely a global effect rather than a direct result of the medications utilized with no evidence that indicates that a specific antihyperglycemic medication works better than another. Further, the mechanism of how and why this relationship exists is not well understood. Specifically, how the microenvironment of the wound as evidenced by changes in the biomarkers has not been delineated.

Januvia (sitagliptin) is an FDA approved antihyperglycemic drug that inhibits the enzyme dipeptidyl peptidase 4 (DPP-4), which is an enzyme that is responsible for the breakdown of glucagon-like peptide (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By blocking this effect, GLP-1 and GIP stimulates the secretion of insulin and suppresses the release of glucagon thereby normalizing blood glucose. The unique properties of this drug decrease the likelihood of hypoglycemia. Therefore, this drug is often used in combination of other antihyperglycemic medications to produce a synergistic effect.

DPP4 is expressed on the membranes of a variety of cell types as well as in soluble form, and cleaves the two N-terminal amino acids, X-ala or X-pro, from a limited number of peptide substrates, usually resulting in their inactivation. A family of DPP4 inhibitors, gliptins, have been shown to preserve the full-length active forms of GLP1 and GIP in patients with type II diabetes, enhancing antihyperglycemic activity. In addition to GLP1 and GIP, important substrates of DPP4 essential for wound healing, and altered in diabetes, include SDF-1α/β (stromal cell derived factor 1), PYY (peptide YY), NPY (neuropeptide Y), GM-CSF (granulocyte macrophage colony stimulating factor), G-CSF (granulocyte colony stimulating factor), and IL3 (interleukin 3) [8-12]. SDF, PYY, and NPY are all important for angiogenesis, while GM-CSF, G-CSF, and IL3 are necessary for leukocyte proliferation and infiltration in the wound bed. The observation that DPP4 can cleave and inactive all of these signaling molecules in vivo suggest that modulation of DPP4 activity will have a direct effect on wound healing.

The prospect that a daily oral medication that improves overall glucose control of a diabetic patient as well as expediting the wound healing process is profound. This study explores this possibility.

This is a prospective, randomized study examining the ability of sitagliptin in expediting the wound healing process in the diabetic patient with a chronic foot wound. This is a single center study of 250 total subjects randomized into 2 arms. It is projected that this study will take 3 years to complete. The two arms will be 1) Januvia (sitagliptin) 100mg q day* and 2) placebo-control q day. Patients with Type II diabetes with a chronic foot ulcer will be enrolled into this study. Each subject will be randomized into one of the two arms and will participate in the study for a maximum of 16 weeks. At the end of 16 weeks subjects will be exited from the study. If at any time during the course of the study the wound heals, the subject will be exited from the study after a 2-week confirmatory visit.

*For moderate renal failure subjects, the sitagliptin dose will be adjusted to 50mg q day.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 1 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of Januvia (Sitagliptin) in Healing Chronic Diabetic Foot Ulcers
• Study Start Date: January 2014
• Actual Primary Completion Date: January 2015
• Actual Study Completion Date: January 2015

Arms and Interventions

Arm	Intervention/treatment
Experimental: Januvia (Sitagliptin); Sitagliptin 100 mg a day for 12 weeks	Drug: Sitagliptin; Comparison of Sitagliptin a dipeptidyl-peptidase four (DPP-4) inhibitor 100mg pill with placebo comparator; Other Name: Januvia
Placebo Comparator: Placebo; Placebo	Drug: Placebo; Sugar pill manufactured to mimick Sitagliptin 100mg pill.

Outcome Measures

Primary Outcome Measures :

1. Percent Wounds Healed [ Time Frame: 12 weeks ]
   Compare the rate of healing as well as percent of wounds healed in Type II diabetic patients with chronic foot ulcerations receiving sitagliptin versus placebo.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 80 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Male or female age >18
• Type II Diabetes with glycated hemoglobin (hemoglobin A1C) of < 11
• Currently on an oral hyperglycemic medication other than sitagliptin
• A chronic wound defined as the lack of wound healing progress of <15% per week or 50% over a month period
• Ankle brachial index of > 0.80
• Wound located on the foot or ankle (Wagner Grade 1,2)
• Able to comply with the requirements of the research trial

Exclusion Criteria:

• Current use of dipeptidyl-peptidase four (DPP-4) inhibitor or glucagon like peptide one (GLP-1)agonist
• End stage renal disease
• Currently enrolled in another research trial that involves treatment of the wound
• Active infection of the wound
• Wound that probes to bone with osteomyelitis (Wagner Grade 3)

Contacts and Locations

Locations

United States, District of Columbia

Medstar Georgetown University Hospital

Washington, District of Columbia, United States, 20007

Sponsors and Collaborators

Georgetown University

Merck Sharp & Dohme Corp.

Investigators

• Principal Investigator: Paul J Kim, DPM; Georgetown University

More Information

• Responsible Party: Paul J. Kim, DPM, Doctor of Podiatric Medicine, Georgetown University
• ClinicalTrials.gov Identifier: NCT02015910
• Other Study ID Numbers: MISP-RC50959
• First Posted: December 19, 2013
• Results First Posted: January 6, 2017
• Last Update Posted: January 6, 2017
• Last Verified: November 2016

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No
• Plan Description: Data was not collected for use in future research and will not be shared.

Additional relevant MeSH terms:

Diabetic Foot; Foot Ulcer; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Vascular Diseases; Cardiovascular Diseases; Leg Ulcer; Skin Ulcer; Skin Diseases; Diabetes Complications; Diabetes Mellitus; Endocrine System Diseases; Diabetic Neuropathies; Foot Diseases; Glucose Metabolism Disorders; Metabolic Diseases; Sitagliptin Phosphate; Hypoglycemic Agents; Physiological Effects of Drugs; Incretins; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Dipeptidyl-Peptidase IV Inhibitors; Protease Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action